Tiffany Wilson, NP
Payments from drug & device makers
Across 451 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$895
- Lilly USA, LLC$876
- GSK$861
- Novo Nordisk$810
- Amgen$780
- plus $2K from 26 others
What the payments were for
- Food & beverage$7,33199%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 71 | $1,179 |
| AstraZeneca | 48 | $895 |
| Lilly USA, LLC | 61 | $876 |
| GSK | 53 | $861 |
| Novo Nordisk | 53 | $810 |
| Amgen | 51 | $780 |
| Pfizer | 25 | $361 |
| Boehringer Ingelheim | 15 | $267 |
| Astellas Pharma US Inc | 11 | $221 |
| Otsuka America Pharmaceutical, Inc. | 6 | $122 |
| Merck | 7 | $120 |
| Abbott | 6 | $120 |
| Phathom Pharmaceuticals, Inc. | 6 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $93 |
| Antares Pharma, Inc. | 3 | $66 |
| Grifols USA, LLC | 2 | $51 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Dexcom, Inc. | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Mylan Specialty L.p. | 2 | $34 |
| Exact Sciences | 2 | $32 |
| Novartis | 2 | $31 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Lundbeck LLC | 1 | $29 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Silk Road Medical, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
How this compares
$7,396 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $79,781 |
| MounjaroTirzepatide | 54 | $70,501 |
| EliquisApixaban | 31 | $39,404 |
| JardianceEmpagliflozin | 21 | $33,230 |
| TrulicityDulaglutide | 18 | $26,192 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $19,052 |
| MyrbetriqMirabegron | 23 | $13,357 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $9,860 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,342 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,028 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 115 | $4,387 |
| Atorvastatin Calcium | 321 | $3,987 |
| Humulin N KwikpenInsulin Nph Human Isophane | 14 | $3,704 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,476 |
| Duloxetine Hcl | 94 | $3,121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $876 | $96,69372 claims |
| Novo NordiskOzempic | $810 | $79,78170 claims |
| PfizerEliquis | $361 | $39,40431 claims |
| Boehringer IngelheimJardiance | $267 | $33,23021 claims |
| GSKTrelegy Ellipta | $861 | $19,05225 claims |
| Astellas Pharma US IncMyrbetriq | $221 | $13,35723 claims |
| AstraZenecaBreztri Aerosphere | $895 | $7,02812 claims |
| AbbVieSynthroid | $1,179 | $1,45523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Cabot
- Kimberly GriffithCabot$14K
- Erica GibsonCabot$11K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.